Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD90 Expression Controls Migration and Predicts Dasatinib Response in Glioblastoma.
Avril T, Etcheverry A, Pineau R, Obacz J, Jegou G, Jouan F, Le Reste PJ, Hatami M, Colen RR, Carlson BL, Decker PA, Sarkaria JN, Vauléon E, Chiforeanu DC, Clavreul A, Mosser J, Chevet E, Quillien V. Avril T, et al. Among authors: vauleon e. Clin Cancer Res. 2017 Dec 1;23(23):7360-7374. doi: 10.1158/1078-0432.CCR-17-1549. Epub 2017 Sep 22. Clin Cancer Res. 2017. PMID: 28939749 Free article.
Characteristics, Patterns of Care and Predictive Geriatric Factors in Elderly Patients Treated for High-Grade IDH-Mutant Gliomas: A French POLA Network Study.
Montégut C, Guillamo JS, Ducray F, Dehais C, Cohen-Jonathan Moyal E, Desenclos C, Petit A, Seizeur R, Bekaert L, Gaultier C, Motuo Fotso MJ, Blonski M, Frenel JS, Vauléon E, Langlois O, Noel G, Carpentier AF, Di Stefano AL, Bronnimann C, Figarella-Branger D, Chinot O, Tabouret E. Montégut C, et al. Among authors: vauleon e. Cancers (Basel). 2022 Nov 9;14(22):5509. doi: 10.3390/cancers14225509. Cancers (Basel). 2022. PMID: 36428602 Free PMC article.
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A; PHARE trial investigators. Pivot X, et al. Lancet Oncol. 2013 Jul;14(8):741-8. doi: 10.1016/S1470-2045(13)70225-0. Epub 2013 Jun 11. Lancet Oncol. 2013. PMID: 23764181 Clinical Trial.
DNA methylation in glioblastoma: impact on gene expression and clinical outcome.
Etcheverry A, Aubry M, de Tayrac M, Vauleon E, Boniface R, Guenot F, Saikali S, Hamlat A, Riffaud L, Menei P, Quillien V, Mosser J. Etcheverry A, et al. Among authors: vauleon e. BMC Genomics. 2010 Dec 14;11:701. doi: 10.1186/1471-2164-11-701. BMC Genomics. 2010. PMID: 21156036 Free PMC article.
[MGMT analysis in gliomas].
Quillien V, Vauléon E, Saikali S, Lesimple T, Hamlat A, Etcheverry A, Mosser J. Quillien V, et al. Among authors: vauleon e. Bull Cancer. 2011 Mar;98(3):291-303. doi: 10.1684/bdc.2011.1332. Bull Cancer. 2011. PMID: 21459716 Review. French.
Mechanisms of immunomodulation in human glioblastoma.
Avril T, Vauleon E, Tanguy-Royer S, Mosser J, Quillien V. Avril T, et al. Among authors: vauleon e. Immunotherapy. 2011 Apr;3(4 Suppl):42-4. doi: 10.2217/imt.11.39. Immunotherapy. 2011. PMID: 21524170 Review.
90 results